Zobrazeno 1 - 10
of 63
pro vyhledávání: '"59"'
Autor:
Luciana Kikuchi, Alice M. Isejima, Paulo M. Hoff, Marcelo Queiroz, Leonardo Gomes da Fonseca, Maria Ignez Braghiroli, Joao Glasberg, Christian Kappeler, Luiz Antonio Senna Leite, Daniela R. Nebuloni, Giovanni M. Bariani, Rachel P. Riechelmann, Thomas Giollo Rivelli
Publikováno v:
The Oncologist. 24:1180-1187
Background Regorafenib is a multikinase inhibitor with antiangiogenic effects that improves overall survival (OS) in metastatic colorectal cancer (mCRC) after failure of standard therapies. We investigated the efficacy and safety of regorafenib in an
Autor:
Scott M. Lippman, Ryosuke Okamura, Razelle Kurzrock, Paul T. Fanta, Lawrence Leichman, In Sil Choi, Richard B. Lanman, Victoria M. Raymond, Shumei Kato
Publikováno v:
Molecular cancer therapeutics, vol 18, iss 10
Molecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool. Here, next-generation sequencing (NGS) of blood-derived ctDNA was performed in patients with advanced colorectal cancer. We investigated ctDNA-derived genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290193aa9ced4e27403ae647b2879efc
https://escholarship.org/uc/item/0mj0j211
https://escholarship.org/uc/item/0mj0j211
Publikováno v:
Annals of Oncology, 28(12), 3083-3091. Oxford University Press
Background: Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Because ADC tumour cell targets do not have to be dri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5326de82539e0cd6dc4c1bcb66077e7c
https://research.rug.nl/en/publications/63b5355a-5f39-4d65-bde8-cb25e403c62c
https://research.rug.nl/en/publications/63b5355a-5f39-4d65-bde8-cb25e403c62c
Autor:
R. Bryan Rumble, Nancy Roach, Pamela B. Mangu, Richard L. Schilsky, Carmen J. Allegra, Alexander Hantel, Stanley R. Hamilton
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(2)
Purpose An American Society of Clinical Oncology Provisional Clinical Opinion (PCO) offers timely clinical direction after publication or presentation of potentially practice-changing data from major studies. This PCO update addresses the utility of
Autor:
Maliha Nusrat, Riham Katkhuda, James P. Allison, Jason Roszik, David G. Menter, Scott Kopetz, Michael J. Overman, Kanwal Pratap Singh Raghav, Van K. Morris, Dipen M. Maru, Padmanee Sharma, Jorge Blando
Publikováno v:
Journal of Clinical Oncology. 36:653-653
653 Background: PI3K pathway is a known modulator of anti-tumor immune response and is frequently activated in CRC through genetic alterations such as PTEN loss (PTENloss) and PIK3CA mutations (PIK3CAmut). This study aims to determine the impact of t
Autor:
Jose Carlos Martinez Avila, Jair Tenorio, Hoi Tong, Lorena Ostios, Nuria Rodriguez Salas, Alberto M. Borobia, María Teresa García Morales, Jesus Miranda, Mario Muñoz, Gema Gordo
Publikováno v:
Journal of Clinical Oncology. 36:718-718
718 Background: mCRC is the 2º cause of death in the world. Development of targeted therapies has increased the survival. The efficacy of these drugs (such Bevacizumab and monoclonal antibodies against EGFR) depends on the use of genetic biomarkers
Autor:
Marco Maria Germani, Alessandra Boccaccino, Giuseppe Aprile, Chiara Cremolini, Salvatore Corallo, Filippo Pietrantonio, Daniele Rossini, Umberto Cillo, Giovanni Centonze, Massimo Milione, Alfredo Falcone, Roberto Moretto, Sara Lonardi, Antonino Belfiore, Michele Prisciandaro, Gabriella Fontanini, Filippo de Braud, Lucio Urbani, Fotios Loupakis, Laura Cattaneo, Federica Morano, Luca Morelli, Silvia Brich, Matteo Fassan, Federica Marmorino
Publikováno v:
European Journal of Cancer. 135:78-88
Immune-contexture of tumour microenvironment (TME) influences prognosis of colorectal cancer (CRC) patients and can be altered by cytotoxic and targeted agents. Limited data are available regarding the immune-TME of CRC after treatment.An extensive i
Autor:
Weihua Dong, Junhe Zhang
Publikováno v:
Recent Patents on Anti-Cancer Drug Discovery. 15:78-85
Background: Colon cancer is one of the most common malignant tumors, and B cell Translocation Gene (BTG)1 is involved in the occurrence and development of colon cancer, however, the underlying molecular mechanism remains unclear. Objective: In this s
Publikováno v:
Journal of Cancer
Aims: To investigate the expression and clinical significance of methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) in colorectal cancer (CRC) and its effect on CRC cells proliferation and migration. Methods: 59 fresh CRC tissue samples and mat
Autor:
Daisuke Kotani, Sandra Romero-Cordoba, Daniele Rossini, Lisa Salvatore, Chiara Cremolini, Filippo de Braud, Siraj M. Ali, Alessandra Raimondi, Seung Tae Kim, Alfredo Falcone, Beatrice Borelli, Rona Yaeger, Jeeyun Lee, Maria Di Bartolomeo, Jaclyn F. Hechtman, Vincent A. Miller, Takayuki Yoshino, Alexa B. Schrock, Filippo Pietrantonio, Federica Perrone, Russell Madison, Giovanni Randon, Filippo Pagani, Jeffrey S. Ross, Giovanni Fucà
Publikováno v:
JCO Precision Oncology. :1-11
PURPOSE To describe the clinical and molecular features of metastatic colorectal cancers (mCRCs) bearing uncommon atypical RAS (At- RAS) mutations at codons other than 12, 13, 59, 61, 117, and 146. MATERIALS AND METHODS By exploiting five next-genera